Small Cell Lung Cancer

Small Cell Lung Cancer - most related articles:

- Lilly's lung cancer drug Alimta is approved in US - 8.5
- Eli Lilly's Alimta approvad for lung cancer - 6.9
- Surgery remans an option for lung cancer patients - 6.7
- PET imaging more accurate in lung cancer staging - 6.6
- Shark cartilage drug AE-941 does not improve lung cancer survival - 6.1
- Stem cell clue to lung cancer development - 5
- Food additives linked to lung cancer risk - 5
- Quitting smoking doubles survival in lung cancer patients - 5
- New early detection studies of lung cancer in nonsmokers - 4.8
- Vitamin supplements may increase lung cancer risk - 4.8

Small Cell Lung Cancer articles

Bevacizumab with chemotherapy provides no survival benefit for lung cancer patients
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) – an approach approved by the FDA in 2006 – did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare.

Shark cartilage drug AE-941 does not improve lung cancer survival
The anti-cancer drug AE-941, a shark cartilage derivative, did not improve overall survival in patients with inoperable stage III non-small cell lung cancer, according to a study published online May_26 in the Journal of the National Cancer Institute.

Thalidomide does not improve survival in lung cancer
Treating patients with thalidomide in combination with chemotherapy for small cell lung cancer (SCLC) did not improve their survival but did increase their risk of blood clots, revealed by researchers.

Vandetanib with docetaxel improve lung cancer survival
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

Eli Lilly's Alimta approvad for lung cancer
Eli Lilly and Company (NYSE: LLY) announced that it received approval from the U.S. Food and Drug Administration (FDA) for the use of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with nonsquamous histology.

5 Small Cell Lung Cancer articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
13.43